Section 3 of 6
Product information and disease description
302 evidence topics · 115 sources
Product description
Phase of product development
Development phase: phase 3 portion of the pivotal phase 2/3 trial
Breakthrough Therapy Designation and designated population
Other expedited program and orphan designations
FDA alignment on the accelerated approval pathway and confirmatory overall survival
Regulatory status: Submission planned; BLA for accelerated approval to follow an interim analysis expected in mid-2027
Alternate dosing study timed to the potential approval
Ongoing phase 1b cohorts outside the pivotal population
Cutaneous squamous cell carcinoma and squamous cancer of the anal canal
Investigator-sponsored trials in head and neck cancer
Product information
Generic, brand name and therapeutic class of product
Manufacturer: Bicara Therapeutics
International nonproprietary name
Development code and substance synonyms
| Registry field | Quoted record |
|---|---|
| Product name | “Ficerafusp Alfa” |
| Sponsor product code | “BCA101” |
| Substance synonym | “Bifunctional monoclonal antibody against epidermal growth factor receptor and transforming growth factor beta” |
Therapeutic class as described by the company
Brand name
No evidence found.
Dosage forms and strengths
Investigational product form and route in the pivotal trial
| Registry field | Quoted record |
|---|---|
| Pharmaceutical form | “VIAL FOR INTRAVENOUS USE” |
| Route | “SOLUTION FOR INFUSION” |
| Active substance origin | “Protein - Other” |
Flat-dose intravenous administration in the phase 1b trial
Vial strength and commercial formulation
No evidence found.
Average sales price and wholesale acquisition cost
Not applicable.
American hospital formulary service (AHFS), or other drug classification
WHO INN use statement
Registry intervention class
AHFS classification
No evidence found.
Indication
Population of the Breakthrough Therapy Designation
Indication pursued in the pivotal trial as described by the company
Pivotal trial primary sites, HPV status, PD-L1 threshold, and prior therapy
HPV-negative disease as the only population enrolled
Pharmacology
Mechanism of action
Molecular structure: cetuximab-based anti-EGFR IgG1 antibody fused to the TGF-beta receptor II extracellular domain
Tumor-directed TGF-beta ligand trap
“Ficerafusp alfa (BCA101) is a first-in-class bifunctional antibody that fuses a TGF-β immune-modulating payload or trap to an EGFR tumor antigen–directed antibody for selective delivery to the tumor microenvironment. Ficerafusp alfa aims to target immunosuppressive mechanisms in the tumor microenvironment mediated by TGF-β1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Retained EGFR activity: inhibition of EGFR signaling and antibody-dependent cellular cytotoxicity
“FaDu cells preincubated with either BCA101 or cetuximab and spiked with EGF showed comparable inhibition of EGFR phosphorylation (Tyr1068).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“BCA101 showed concentration-dependent ADCC activity in the reporter-based ADCC assay comparable with that of cetuximab (Fig. 2D)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
TGF-beta isoform selectivity: TGF-beta1 and TGF-beta3 neutralized, TGF-beta2 spared
Preclinical immune effects and rationale for combination with PD-1 blockade
“BCA101 increased production of proinflammatory cytokines and key markers associated with T-cell and natural killer–cell activation, while suppressing VEGF secretion. In addition, BCA101 inhibited differentiation of naïve CD4+ T cells to inducible regulatory T cells (iTreg) more strongly than the anti-EGFR antibody cetuximab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The combination of BCA101 and anti-PD1 antibody improved tumor inhibition in both B16-hEGFR–expressing syngeneic mouse models and in humanized HuNOG-EXL mice bearing human PC-3 xenografts.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Combination partner: pembrolizumab
Pharmacodynamics
Preclinical intratumoral TGF-beta neutralization and durable response in head and neck xenografts
“TGFβ in tumors was neutralized by approximately 90% in animals dosed with 10 mg/kg of BCA101 compared with 54% in animals dosed with equimolar TGFβRII-Fc.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patient-derived xenograft mouse models of head and neck squamous cell carcinoma, BCA101 showed durable response after dose cessation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Plasma TGF-beta1 neutralization by dose in the phase 1 dose escalation
“Patients treated with ficerafusp alfa achieved complete and prolonged neutralization of TGF-β1 in plasma at weekly doses of ≥500 mg (Fig. 3A). Minimal neutralization of TGF-β2 was observed at doses of ≥500 mg (Fig. 3B). TGF-β3 levels were close to the lower limit of quantification and therefore not analyzed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EGFR target saturation inferred from exposure at doses of 500 mg or more
Plasma TGF-beta1 and tumor pSMAD2 in the 1500 mg weekly first-line HNSCC cohort
Tumor pSMAD2, CD8 T-cell infiltration, and circulating immune markers across the 750 mg, 1500 mg, and 2000 mg cohorts
Company-reported biomarker comparison of 1500 mg and 750 mg weekly
Pharmacokinetics
Time to maximum concentration and half-life in the phase 1 dose escalation
“Maximal concentrations (Cmax) were generally reached between 2 and 5 hours after the start of infusion on cycle 1 day 1. Thereafter, the concentration–time profiles declined in a biexponential manner at higher doses, with geometric mean half-life ranging from 14 hours for lower doses associated with target-mediated drug disposition to 84 hours for higher doses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company-reported half-life of about eight days
Dose proportionality and target-mediated drug disposition
“Cmax and area under the plasma concentration versus time curve from 0 to 168 hours (AUC0–168h) increased in a slightly more than dose-proportional manner between 64 and 500 mg. However, a nearly dose-proportional increase in Cmax and AUC0–168h was observed between 500 and 1,500 mg. These data suggest that nonlinear clearance is negligible and linear clearance dominates at doses above 500 mg as EGFR is likely fully saturated.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of note, ficerafusp alfa showed a nonlinear PK profile consistent with target-mediated drug disposition at doses <500 mg. Specifically, nonoverlapping exposures were achieved at 750 and 1,500 mg once weekly dosages.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immunogenicity
Nonclinical pharmacokinetics in cynomolgus monkeys
“Following a single intravenous infusion of BCA101 to cynomolgus monkeys, serum mean maximum concentrations and mean exposures of the molecule increased dose proportionally (Supplementary Fig. S17), with no saturation of the routes of elimination. The observed volumes of distribution (33–74 mL/kg) suggest that BCA101 is well distributed to the tissues. Half-life of BCA101 ranged from 12.9 to 84.5 hours for the doses tested.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Dose-selection rationale for 1500 mg weekly
“As a result, ficerafusp alfa 1,500 mg once weekly was selected as the recommended dosage based on the PK, pharmacodynamic, and preliminary antitumor activity observed at this dosage level and will continue to be assessed for safety and efficacy during dose expansion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharmacokinetic basis for less frequent dosing regimens
“Based on available PK results from 1,500 to 1,750-mg every-2-week cohorts, the every-2-week dosing regimen is expected to reach non–clinically derived target concentrations (Supplementary Fig. S2A and S2B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pembrolizumab half-life and steady state
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Not applicable.
Special populations
Pregnancy and breastfeeding: protocol exclusions
Hepatic and renal function: protocol requirements
Age of participants in the phase 1b 1500 mg cohort
Pembrolizumab label: pregnancy, lactation, and contraception
Pembrolizumab label: older adults, renal impairment, and hepatic impairment
Drug/Drug, drug/disease interactions
Effects of other drugs on Ficerafusp alfa
Ficerafusp alfa exposure with and without pembrolizumab
Protocol restrictions on systemic corticosteroids, immunosuppressants, and live vaccines
Concomitant anticoagulation
Effects of Ficerafusp alfa on other drugs
Toxicity of pembrolizumab when given with ficerafusp alfa
Effect on pembrolizumab pharmacokinetics or on cytochrome P450 substrates
No evidence found.
Dosing and administration
Dosage
FORTIFI-HN01 pivotal regimen
| Arm | Regimen |
|---|---|
| Phase 2 Arm A | “ficerafusp alfa 1500 mg QW + pembrolizumab 200 mg every 3 weeks (Q3W)” |
| Phase 2 Arm B | “ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W” |
| Phase 2 Arm C | “placebo QW + pembrolizumab 200 mg Q3W” |
| Phase 3 optimal biological dose arm | “ficerafusp alfa OBD + pembrolizumab 200 mg Q3W” |
| Phase 3 Arm C | “placebo QW + pembrolizumab 200 mg Q3W” |
Doses studied in the phase 1b first-line HNSCC expansion cohorts
| Cohort | Ficerafusp alfa | Pembrolizumab |
|---|---|---|
| 750 mg weekly | “Ficerafusp alfa 750 mg QW” | “Pembrolizumab 200 mg Q3W” |
| 1500 mg weekly | “Ficerafusp alfa 1500 mg QW” | “Pembrolizumab 200 mg Q3W” |
| 2000 mg every 2 weeks | “Ficerafusp alfa 2000 mg Q2W” | “Pembrolizumab 400 mg Q6W” |
Doses studied in the phase 1 dose escalation
“At escalating doses in a parallel 3 + 3 design, patients with EGFR-driven advanced solid tumors received weekly intravenous ficerafusp alfa as monotherapy (64–1,500 mg) or in combination (240–1,500 mg) with pembrolizumab (200 mg i.v. every 3 weeks).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The MTD was not reached in either cohort.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Loading and every-3-week maintenance regimen under study in FORTIFI-FLEX
Dose modification rules in the phase 1b
Administration
Intravenous infusion over 120 minutes, with pembrolizumab given afterward
“Ficerafusp alfa was administered as an infusion over 120 minutes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pembrolizumab 200 mg i.v. was administered after ficerafusp alfa as a 30-minute infusion every 3 weeks (cycle length, 21 days).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prophylaxis and premedication
Access and distribution
Compassionate use and expanded access
License from Biocon
Manufacturing and supply
Commercial distribution arrangements and patient assistance
No evidence found.
Co-prescribed/Concomitant therapies
Pembrolizumab first-line HNSCC indications in the U.S. label
Pembrolizumab labeled dose for HNSCC
Pembrolizumab supply for the trials
Supportive therapy for acneiform dermatitis
Pembrolizumab label warnings that apply to the combination
Effect of Ficerafusp alfa on quality measures
Product-specific effects on healthcare quality measures
No evidence found.
Product comparison
Competing products named by the sponsor
Ficerafusp alfa plus pembrolizumab: population definition and phase 1b HPV-negative results
Pembrolizumab-based regimens in HPV-negative disease: outcomes cited by the ficerafusp alfa phase 1b report
Pembrolizumab monotherapy: approved first-line indication
Pembrolizumab monotherapy: KEYNOTE-048 survival and response in the CPS 1 or greater population at 4-year follow-up
“The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pembrolizumab plus platinum and fluorouracil: approved first-line indication
Pembrolizumab plus platinum and fluorouracil: KEYNOTE-048 survival and response at 4-year follow-up
“The median OS was 14.7 months (95% CI, 10.3 to 19.3) for pembrolizumab-chemotherapy versus 11.1 months (95% CI, 9.2 to 13.0) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.62; 95% CI, 0.46 to 0.84; nominal one-sided P = .00082), 13.6 months (95% CI, 10.7 to 15.5) versus 10.6 months (95% CI, 9.1 to 11.7) in the CPS ≥ 1 population (HR, 0.64; 95% CI, 0.53 to 0.78; nominal one-sided P = .00001), and 13.0 months (95% CI, 10.9 to 14.7) versus 10.7 months (95% CI, 9.3 to 11.7) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 43.7% (13 CR/42 PR) for pembrolizumab-chemotherapy versus 38.2% (4 CR/38 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 37.2% (17 CR/73 PR) versus 35.7% (7 CR/77 PR) in the CPS ≥ 1 population, and 36.3% (18 CR/84 PR) versus 36.3% (8 CR/93 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KEYNOTE-048 population: HPV status and PD-L1 distribution
“Eligible patients were age ≥ 18 years with previously untreated R/M squamous cell carcinoma of the oropharynx (known p16 expression), oral cavity, hypopharynx, or larynx, which was incurable by local therapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Random assignment was stratified by PD-L1 expression (tumor proportion score ≥ 50% v < 50%), p16 expression for oropharyngeal cancer (positive v negative), and Eastern Cooperative Oncology Group performance status (0 v 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cetuximab plus platinum and fluorouracil (EXTREME): approved first-line indication and population
Cetuximab plus platinum and fluorouracil (EXTREME): efficacy results
| Outcome | Result |
|---|---|
| Median overall survival, cetuximab with platinum-based therapy and fluorouracil (n=222), months | “10.1” |
| Median overall survival, platinum-based therapy and fluorouracil (n=220), months | “7.4” |
| Overall survival hazard ratio (95% CI) | “0.80 (0.64, 0.98)” |
| Median progression-free survival, cetuximab arm, months | “5.5” |
| Median progression-free survival, control arm, months | “3.3” |
| Objective response rate, cetuximab arm | “35.6%” |
| Objective response rate, control arm | “19.5%” |
Petosemtamab plus pembrolizumab: LiGeR-HN1 phase 3 topline results
Petosemtamab plus pembrolizumab: LiGeR-HN1 eligibility and HPV classification
“p16 status is measured only in patients with oropharyngeal tumors; all other tumor locations are designated as p16 negative for the purposes of stratification.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Randomization will be stratified based on p16 status (positive vs. negative) and PD-L1 CPS (<20 vs. ≥20), as determined by central laboratory testing, and ECOG PS (0 vs. 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Petosemtamab plus pembrolizumab: phase 2 first-line cohort
Amivantamab plus pembrolizumab: OrigAMI-4 cohort 2, first-line, p16-positive oropharyngeal cancer excluded
“Cohort 2 of the phase 1b/2 OrigAMI-4 (NCT06385080) study enrolled participants with previously untreated R/M HNSCC and PD-L1 combined positive score ≥1.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Patients with p16-positive oropharyngeal cancer and prior anti-EGFR or anti-PD-(L)1 therapy were excluded.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At a median follow-up of 13.6 months, confirmed ORR was 59% (95% CI, 42-74), with 7 (18%) complete responses.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median PFS was 7.7 months (95% CI, 5.0-NR); median OS was NR.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Amivantamab plus pembrolizumab and carboplatin: OrigAMI-4 cohort 5, first-line
Amivantamab plus pembrolizumab and carboplatin: OrigAMI-5 phase 3 design and population
Amivantamab and hyaluronidase: accelerated approval in previously treated disease
| Outcome | RYBREVANT FASPRO (N=102) |
|---|---|
| Overall response rate (95% CI) | “42% (32%, 52%)” |
| Complete response | “15%” |
| Partial response | “28%” |
| Patients with duration of response of 6 months or longer | “56%” |
Enfortumab vedotin plus pembrolizumab: EV-202 first-line cohort
“Eligible patients had R/M HNSCC, programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥1, and no prior systemic therapy in the R/M setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary analysis included 41 patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Sixteen patients achieved a response, and cORR was 39% [95% confidence interval (CI), 24.2–55.5]. The complete response rate was 9.8%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median PFS was 5.1 months (95% CI, 3.5–not estimable).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with p16-positive oropharyngeal cancer ( n = 11), the cORR was 81.8%, in contrast to 23.3% in patients with non-HPV–associated disease ( n = 30).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“b For oropharyngeal squamous cell carcinoma only, patients without oropharyngeal cancer were considered HPV–negative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients also did not undergo any testing to confirm their HPV status.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HPV16-positive first-line combinations with pembrolizumab: BNT113
HPV16-positive first-line combinations with pembrolizumab: PDS0101
HPV-negative disease after PD-1 inhibitor and platinum: ficlatuzumab plus cetuximab
Place of product in therapy
Disease description
Definition and etiology
Definition of head and neck squamous cell carcinoma and its HPV-negative and HPV-positive forms
“Most head and neck cancers are derived from the mucosal epithelium in the oral cavity, pharynx and larynx and are known collectively as head and neck squamous cell carcinoma (HNSCC).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Oral cavity and larynx cancers are generally associated with tobacco consumption, alcohol abuse or both, whereas pharynx cancers are increasingly attributed to infection with human papillomavirus (HPV), primarily HPV-16. Thus, HNSCC can be separated into HPV-negative or HPV-positive HNSCC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Primary sites of HPV-negative disease
Tobacco and alcohol as the principal causes of HPV-negative disease
Combined tobacco and alcohol exposure, all oral cavity and pharynx cancer
Combined tobacco and alcohol exposure and other environmental risk factors, all HNSCC
“Tobacco and alcohol consumption are the high-risk factors that occur most widely geographically. Of note, heavy users of both substances have >35-fold higher risk of developing HNSCC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In general, the high male:female ratios for HPV-negative HNSCC incidence reflect the sex-specific patterns of modifiable risk behaviours, including the use of the aforementioned tobacco, smokeless tobacco, areca nut, betel quid and alcohol” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HPV as a cause confined to the oropharynx
Epidemiology
Incidence of HPV-negative head and neck squamous cell carcinoma
Estimated U.S. new cases in 2026, all oral cavity and pharynx cancer
Estimated U.S. new cases in 2026 by subsite, all oral cavity, pharynx, and laryngeal cancer
U.S. incidence rate, all oral cavity and pharynx cancer
U.S. incidence rate, all laryngeal cancer
U.S. incidence trends, all oral cavity and pharynx cancer
U.S. incidence trend of HPV-negative oropharyngeal cancer
“Population-level incidence of HPV-positive oropharyngeal cancers increased by 225% (95% CI, 208% to 242%) from 1988 to 2004 (from 0.8 per 100,000 to 2.6 per 100,000), and incidence for HPV-negative cancers declined by 50% (95% CI, 47% to 53%; from 2.0 per 100,000 to 1.0 per 100,000).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HPV-negative share of U.S. oropharyngeal squamous cell carcinoma
| Oropharynx, United States, 2012 to 2016 | Quoted value |
|---|---|
| Average annual reported cases | “19,000”View highlighted excerpt for this quote |
| Attributable to 9vHPV-targeted types, number (%) | “12,600 (66)”View highlighted excerpt for this quote |
| Attributable to other HPV types, number (%) | “900 (5)”View highlighted excerpt for this quote |
| HPV-negative, number (%) | “5,500 (29)”View highlighted excerpt for this quote |
HPV-positive share in a first-line recurrent or metastatic HNSCC trial population
HPV status among U.S. real-world first-line pembrolizumab recipients with recurrent or metastatic HNSCC
| HPV status, all subtypes | All patients, n (%) | Pembrolizumab monotherapy, n (%) | Pembrolizumab plus chemotherapy, n (%) |
|---|---|---|---|
| Positive | “233 (36.1)”View highlighted excerpt for this quote | “163 (37.8)”View highlighted excerpt for this quote | “70 (32.6)”View highlighted excerpt for this quote |
| Negative | “258 (39.9)”View highlighted excerpt for this quote | “165 (38.3)”View highlighted excerpt for this quote | “93 (43.3)”View highlighted excerpt for this quote |
| Equivocal or unknown | “155 (24.0)”View highlighted excerpt for this quote | “103 (24.9)”View highlighted excerpt for this quote | “52 (24.2)”View highlighted excerpt for this quote |
Company-stated HPV-negative share of recurrent or metastatic HNSCC
Median age at diagnosis by etiology, all HNSCC
Global new cases in 2024 by subsite, all histologies
| GLOBOCAN 2024 cancer site | New cases | Percentage of all cases |
|---|---|---|
| Lip, oral cavity | “452,205”View highlighted excerpt for this quote | “2.2”View highlighted excerpt for this quote |
| Larynx | “193,937”View highlighted excerpt for this quote | “0.9”View highlighted excerpt for this quote |
| Oropharynx | “107,887”View highlighted excerpt for this quote | “0.5”View highlighted excerpt for this quote |
| Hypopharynx | “91,464”View highlighted excerpt for this quote | “0.4”View highlighted excerpt for this quote |
Metastatic disease at diagnosis and recurrence after initial therapy, all HNSCC
Recurrence after primary treatment of locoregionally advanced HNSCC in U.S. adults aged 66 years or older
“In the resected cohort, 333 patients (66%) experienced recurrence following their primary treatment, compared with 169 (34%) who remained recurrence-free throughout the follow-up period. In the unresected cohort, 791 patients (65%) developed recurrence and 426 did not (35%)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company-stated metastasis and recurrence rates, all HNSCC
Prevalence of HPV-negative head and neck squamous cell carcinoma
U.S. prevalence in 2023, all oral cavity and pharynx cancer
U.S. prevalence in 2023, all laryngeal cancer
Prevalence of HPV-negative or recurrent or metastatic disease
No evidence found.
PD-L1 combined positive score distribution in a first-line recurrent or metastatic HNSCC trial population
PD-L1 combined positive score distribution among U.S. real-world first-line pembrolizumab recipients
Natural history, survival, and mortality
Estimated U.S. deaths in 2026 and death rate, all oral cavity and pharynx cancer
Estimated U.S. deaths in 2026 and death rate, all laryngeal cancer
| Measure | Quoted value |
|---|---|
| Estimated deaths in 2026 | “3,960” |
U.S. mortality trends, all oral cavity and pharynx cancer
Survival trend attributed to the changing share of smoking-related cancers, all oral cavity cancer
“For example, the increase in survival for people diagnosed with oral cavity cancers from 58% in the mid‐1990s to 69% in 2015–2021 partly reflects a decreased proportion of smoking‐related cancers and an increased proportion of HPV infection‐associated cancers, which typically have a better prognosis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Global deaths in 2024 by subsite, all histologies
| GLOBOCAN 2024 cancer site | Deaths | Percentage of all deaths |
|---|---|---|
| Lip, oral cavity | “194,108”View highlighted excerpt for this quote | “2.0”View highlighted excerpt for this quote |
| Larynx | “96,619”View highlighted excerpt for this quote | “1.0”View highlighted excerpt for this quote |
| Oropharynx | “51,823”View highlighted excerpt for this quote | “0.5”View highlighted excerpt for this quote |
| Hypopharynx | “49,748”View highlighted excerpt for this quote | “0.5”View highlighted excerpt for this quote |
HPV-negative versus HPV-positive survival, locally advanced oropharyngeal cancer treated with chemoradiotherapy
HPV-negative versus HPV-positive survival, population-based U.S. oropharyngeal cancer
“Median survival was significantly longer for HPV-positive than for HPV-negative patients (131 v 20 months; log-rank P < .001; adjusted hazard ratio, 0.31; 95% CI, 0.21 to 0.46). Survival significantly increased across calendar periods for HPV-positive (P = .003) but not for HPV-negative patients (P = .18).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Survival after recurrence of locoregionally advanced HNSCC in U.S. adults aged 66 years or older
“Within the resected cohort, patients with recurrence had a median OS of 23.8 months vs 44.4 months for patients without recurrence (P = 0.008); the 5-year OS rate was 30.2% compared with 42.5%, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Similarly, in the unresected cohort, the median OS was 23.7 months for patients with recurrence compared with 64.5 months for those without (P < 0.001), and the 5-year OS rate was 30.6% compared with 50.8%, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Median overall survival with first-line pembrolizumab regimens in recurrent or metastatic HNSCC at 4-year follow-up
“The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080), and 11.5 months (95% CI, 10.3 to 13.5) versus 10.7 months (95% CI, 9.3 to 12.1) in the total population (HR, 0.81; 95% CI, 0.68 to 0.97; nominal one-sided P = .00994; Figs 2A-2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median OS was 14.7 months (95% CI, 10.3 to 19.3) for pembrolizumab-chemotherapy versus 11.1 months (95% CI, 9.2 to 13.0) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.62; 95% CI, 0.46 to 0.84; nominal one-sided P = .00082), 13.6 months (95% CI, 10.7 to 15.5) versus 10.6 months (95% CI, 9.1 to 11.7) in the CPS ≥ 1 population (HR, 0.64; 95% CI, 0.53 to 0.78; nominal one-sided P = .00001), and 13.0 months (95% CI, 10.9 to 14.7) versus 10.7 months (95% CI, 9.3 to 11.7) in the total population (HR, 0.71; 95% CI, 0.59 to 0.85; nominal one-sided P = .00008; Figs 2D-2F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Five-year overall survival with first-line pembrolizumab regimens in recurrent or metastatic HNSCC
Real-world overall survival with first-line pembrolizumab by HPV status in recurrent or metastatic HNSCC
“Among those receiving pembrolizumab monotherapy, the median rwOS was 20 months for those with HPV-positive tumors versus 9 months for those with HPV-negative tumors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among individuals receiving pembrolizumab plus chemotherapy, the median rwOS was 15 months for those with HPV-positive tumors versus 7 months for those with HPV-negative tumors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pathophysiology
Genomic alterations of HPV-negative tumors
“HPV-negative tumours are enriched for CDKN2A and TP53 alterations, frequent focal deletions in other TSGs (such as NSD1, FAT1, NOTCH1 and SMAD4) and frequent focal amplification of the genes encoding the receptor tyrosine kinases EGFR, HER2 (also known as ERBB2) and FGFR1” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Field cancerization in HPV-negative disease
“Rather, HPV-negative HNSCC arises from the grossly normal upper aerodigestive mucosa subject to ‘epithelial field cancerization’, where chronic exposure to carcinogens has resulted in molecular changes preconditioning towards malignant progression” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
EGFR, TGF-beta, and immune exclusion in HPV-negative disease
TGF-beta in immune evasion and resistance to EGFR antibodies
“Factors in the HNSCC TME, including IL-10 and TGFβ, also promote macrophage polarization to the immunosuppressive M2 phenotype” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Specifically, it has been shown that elevated levels of TGF-β in the TME are associated with immune evasion and resistance to cetuximab therapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“TGF-β can also induce EMT through its transactivation of EGFR, synergistically leading to increased tumor invasion and therapy resistance” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
TGF-beta-mediated resistance to cetuximab in preclinical models
Diagnosis
HPV testing of oropharyngeal carcinoma by p16 immunohistochemistry
“Recommendation 2. For oropharyngeal tissue specimens (i.e. non-cytology), including regional lymph nodes with metastatic SCC and clinical findings consistent with an oropharyngeal primary, pathologists should perform HR-HPV testing by surrogate marker p16 IHC. In certain scenarios HPV-specific testing should be performed: (1) in geographic regions with a low prevalence of HR-HPV–associated OPSCC; (2) when p16 IHC is equivocal (50%–70% staining or when staining is extensive but weak); (3) when there is a discrepancy between p16 IHC and morphology; (4) for large, multisite tumors overlapping the oropharynx; (5) when specimens are from a non-tonsillar, non–base of tongue oropharyngeal site; and (6) when required by clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For an OPSCC with classic characteristics, p16 IHC remains the optimal option for HR-HPV testing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
No routine HPV testing of oral cavity, laryngeal, and hypopharyngeal carcinoma
“Recommendation 8. Pathologists should not routinely perform HR-HPV testing on patients with primary oral cavity, laryngeal, nasopharyngeal, or hypopharyngeal SCCs of the head and neck for prognostic purposes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unlike the oropharynx, identifying HPV in primary oral cavity, laryngeal, and hypopharyngeal SCCs does not have clear and consistent implications for patient prognosis or patient management” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HPV-specific test methods
“Recommendation 12. For HPV-specific testing, pathologists should use tests that exhibit optimal performance characteristics—such as RNA-ISH or DNA PCR—and have adequate coverage of non–HPV 16 high-risk types. DNA-ISH is not recommended.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
FDA-approved PD-L1 companion diagnostic for pembrolizumab in HNSCC
| Field | Quoted entry |
|---|---|
| Diagnostic name | “PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)” |
| Indication and specimen | “Head and Neck Squamous Cell Carcinoma (HNSCC) - Tissue” |
| Drug | “Keytruda (pembrolizumab) BLA 125514” |
| Biomarker | “PD-L1 protein expression [Combined Positive Score (CPS) ≥ 1]” |
| Approval | “P150013/S014 (06/10/2019)” |
PD-L1 and p16 assessment in the first-line pembrolizumab registration trial
PD-L1 testing patterns in U.S. recurrent or metastatic HNSCC
Clinical presentation - signs and symptoms
General symptoms: neck mass, nonhealing sore, dysphagia, and voice change
Oral cavity tumors: nonhealing ulcer and impaired chewing and speech
“Cancers of the oral cavity, including the mobile tongue, floor of mouth, buccal mucosa, alveolar ridges, retromolar trigone and hard palate, classically present with a non-healing mouth sore or ulcer. Oral cavity tumours are often diagnosed at an early stage due to the patient’s self-identification of the mass lesion and symptoms that interfere with the fundamental functions of eating and speaking, such as pain with chewing or dysarthria (difficulty speaking).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pharyngeal tumors: dysphagia, odynophagia, and otalgia
“Primary tumours of the oropharynx, including the base of the tongue, the palatine tonsils, the soft palate and the hypopharynx, typically become symptomatic at a later stage, owing to their hidden anatomical location. When present, symptoms such as dysphagia (difficulty eating), odynophagia (pain when swallowing) or otalgia (ear pain) often herald a more advanced tumour.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Laryngeal tumors: hoarseness and airway obstruction
“Patients with cancers of the larynx frequently present with voice changes or florid hoarseness, resulting in diagnosis at an early stage. If tumours are neglected, patients can present with dyspnea (difficulty breathing) and, ultimately, airway obstruction, prompting tracheostomy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Site-specific symptoms: oral cavity, pharynx, and larynx
Recurrent HPV-negative disease: bleeding, pain, dysphagia, and cachexia (company-stated)
Long-term morbidity
Severe late toxicity after concurrent chemoradiotherapy
“Severe late toxicity was defined in this secondary analysis as chronic grade 3 to 4 pharyngeal/laryngeal toxicity (RTOG/European Organisation for the Research and Treatment of Cancer late toxicity scoring system) and/or requirement for a feeding tube ≥ 2 years after registration and/or potential treatment-related death (eg, pneumonia) within 3 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 230 patients were assessable for this analysis: 99 patients with severe late toxicities and 131 controls; thus, 43% of assessable patients had a severe late toxicity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Swallowing, speech, and voice impairment in survivors
“Swallowing and speech impairments occur in ~50% of HNSCC survivors following radiotherapy treatment and are often present long-term” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For example, a majority (68%) of HNSCC survivors reported voice problems even 10 years after radiotherapy” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Furthermore, the two-year prevalence of dysphagia is 45% among HNSCC survivors (all therapies) and is 4–8 times more likely to occur in these individuals than in those who never had cancer” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Chronic dysphagia and aspiration after combined modality therapy
Lymphedema and other long-term effects of surgery and radiotherapy
Second primary tumors after HPV-negative disease
Suicide among survivors
“In addition to deaths directly caused by HNSCC, survivors of this cancer have the second highest rate of suicide (63.4 cases per 100,000 individuals) after those with pancreatic cancer (86.4 cases per 100,000 individuals), compared with survivors of other cancers (23.6 cases per 100,000 individuals).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Burden of HPV-negative head and neck squamous cell carcinoma
Humanistic burden and health-related quality of life
KEYNOTE-048 health-related quality of life instruments and endpoints
“HRQoL was measured using the European Organisation for Research and Treatment of Cancer 30-question quality-of-life (EORTC QLQ-C30), the EORTC 35-question quality-of-life head and neck cancer-specific module (EORTC QLQ-H&N35), and the EuroQol 5-dimension 3-level instruments (EQ-5D-3L).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Secondary endpoints included mean change from baseline in EORTC QLQ-C30 global health status/quality of life (GHS/QoL) at week 15 and time to deterioration (TTD) in EORTC QLQ-C30 GHS/QoL and EORTC QLQ-H&N35 pain and swallowing.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
KEYNOTE-048 global health status at week 15 and time to deterioration
“Of 882 enrolled participants, 844 received ≥ 1 dose of study treatment and completed ≥ 1 HRQoL assessment; adherence was ≥ 79% at week 15 across treatment groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 15, EORTC QLQ-C30 GHS/QoL scores remained stable; no clinically meaningful between-group differences were observed (least squares mean difference, pembrolizumab vs cetuximab-chemotherapy, 0.24; 95% CI, -3.34 to 3.82; pembrolizumab-chemotherapy vs cetuximab-chemotherapy, 0.40; 95% CI, -3.46 to 4.26).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median TTD in EORTC QLQ-C30 GHS/QoL and EORTC QLQ-H&N35 pain and swallowing scores was not reached over 51 weeks across groups, showing stable HRQoL.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“TTD was similar between groups for EORTC QLQ-C30 GHS/QoL (pembrolizumab vs cetuximab-chemotherapy: HR, 1.38; 95% CI, 0.95-2.00; pembrolizumab-chemotherapy vs cetuximab-chemotherapy: HR, 1.37; 95% CI, 0.94-2.00), as was TTD in EORTC QLQ-H&N35 pain and swallowing scores.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Real-world quality of life during pembrolizumab treatment
“We retrospectively analyzed the data of patients with recurrent or metastatic head and neck cancer who underwent pembrolizumab treatment at our institution between 2020 and 2023.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 68 patients were included in the analysis. The mean GHS score increased from 57.0 at baseline to 62.5 at nine weeks, indicating a trend toward improvement (p=0.051). The GHS score remained higher at 18 weeks (58.7) than at baseline, although the difference was not statistically significant.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-state utility values in head and neck cancer
“Of a total 1048 records identified by the search, 28 studies qualified for data extraction and 346 unique HSUVs were retrieved from them.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There is currently a lack of research for some disease phases including recurrent and metastatic cancer, and treatment-related complications.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Utilities used in US cost-effectiveness models of first-line treatment
Time spent on care during immune checkpoint inhibitor treatment
“Of 56 patients evaluated, median age was 63 years (33–85) and 84% were male. Median overall survival (OS) and grade 3 immune-toxicities were 7.6 months and 6.2%, respectively. Median TT was 24 days (1–109), accounting for 7.6% of OS. TT accounted for 14.9% of OS in poor responders.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic burden and healthcare resource utilization
Monthly cost of care in recurrent or refractory disease in US community oncology
“This retrospective observational study was conducted by using data from the Vector Oncology Data Warehouse.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Through the overall study period (mean, 20.5 months), 74% of patients were hospitalized, 19% had an emergency department visit, and 100% had an office visit.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The mean monthly health care cost for the overall study period was $14,391 (95% CI, 12,739-16,044). Hospitalization costs represented ~57% of the total expenditures.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Resource use and costs before and after immuno-oncology agents
“Of 716 patients identified (pre-IO = 265, post-IO = 451) 46.3% of post-IO patients received IO post-platinum.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Inpatient admissions during 1 L PPT: 34.1% post-IO versus 48.0% pre-IO (p= <.01). PPPM total costs of care in 1 L PPT were significantly greater post-IO ($11,535) compared to pre-IO ($9,054, p=.002).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Incremental costs of metastatic and recurrent disease in Medicare and commercial claims
“Administrative claims from Medicare- and privately-insured individuals during 2004-2008 were used in this retrospective database study of patients with advanced HNC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 6-month incremental adjusted total costs were $60,414 per patient for mHNC and $21,141 per patient for rHNC (p<0.0001). Approximately 46-58% of the incremental cost was attributable to outpatient visits, 27-37% to inpatient costs and 11-13% to pharmacy, depending on the HNC cohort.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Costs associated with recurrence in older patients in SEER-Medicare
“Older patients diagnosed with LA HNSCC (2007-2019) from the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recurrence was associated with higher HCRU and monthly health care costs in both resected ($3,831; 95% CI = $2,319-$5,360) and unresected ($4,730; 95% CI = $3,611-$5,870) groups (P < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Systematic review of head and neck cancer costs
“Data from these studies suggested that costs generally are higher for HNC patients with recurrent and/or metastatic disease, for patients undergoing surgery, and for those patients insured by private payers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of first-line pembrolizumab from a US payer perspective
“A three-state partitioned-survival model was used to project costs and outcomes over 20 years with 3% annual discounting.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In the CPS ≥1 R/M HNSCC population, pembrolizumab monotherapy was dominant vs. EXTREME and TPEx regimens, and cost-effective (at $100,000/QALY threshold) vs. platinum+5-FU ($86,827/QALY) and cisplatin + paclitaxel ($81,473/QALY).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Pembrolizumab combination therapy in the overall R/M HNSCC population was dominant vs. TPEx regimen, and cost-effective vs. EXTREME regimen ($1769/QALY), platinum+5-FU ($81,989/QALY), and cisplatin + paclitaxel ($89,505/QALY).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of first-line pembrolizumab by PD-L1 combined positive score
“When compared with cetuximab plus chemotherapy, the pembrolizumab monotherapy strategy was dominated by lower cost and better efficacy in all three populations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incremental costs and quality adjusted life years (QALYs) yielded by pembrolizumab plus chemotherapy compared with cetuximab plus chemotherapy were $16016.88 and 0.11 in the total population, and $24467.47 and 0.18 and $30448.46 and 0.20 in the populations with a PD-L1 CPS ≥ 1 and CPS ≥ 20, respectively, leading to ICERs of $147876.14, $134237.84, and $153660.78 per QALY, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of HPV-negative head and neck squamous cell carcinoma on families
Employment and productivity after recurrence in patients and caregivers
“Although these results did not significantly differ based on cancer type, the highest proportions of patients noting that recurrence affected employment had gastric cancer (68.4%), HN cancer (66.7%), or TNBC (57.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The greatest impacts on the work productivity score were reported for those caring for people with HN cancer (mean [SD] score: 6.5 [2.1]) and TNBC (6.1 [2.5]) and on the activity score for those caring for people with HN cancer (6.1 [1.8]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“From pre- to post-first recurrence, the proportion of caregivers working full-time decreased significantly from 86.1% to 3.0%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Financial toxicity in patients and caregivers
“At diagnosis, the median COST score was 17 (range, 2-41), and 31 (48%) reported high FT by FDQ.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mixed-effects logistic modeling showed similar odds of high FT over time for patients and caregivers (odds ratio, 1.66; 95% CI, 0.11-273.14).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket expenses compared with other cancers
“Median annual medical expenses ($8384 vs $5978; difference, $2406; 95% CI, $795-$4017) and relative out-of-pocket expenses (3.93% vs 3.07%; difference, 0.86%; 95% CI, 0.06%-1.66%) were higher for patients with HNC than for patients with other cancers.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Out-of-pocket costs during survivorship in commercial claims
“Throughout the survivorship period, median total and OOP costs were $372 per month and $31 per month higher than baseline costs, respectively, with variation in expenses by demographic information, health plan type, and oncologic variables.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Psychological burden of caregivers
“Fifty studies (15 cohort studies, 35 cross-sectional studies), including 4289 informal caregivers, were included in the review.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Findings from these studies indicated a high prevalence of clinically significant distress among HNC caregivers: anxiety symptoms meeting clinical thresholds affected 29% to 63% of participants, while clinically significant depression was reported in 10% to 39% of cases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Economic impact of diagnostic testing
PD-L1 testing requirement in the pembrolizumab label
PD-L1 testing patterns before first-line therapy in US practice
“Adults with R/M HNSCC initiating 1L systemic therapy were included from a U.S. nationwide database primarily compromised of community practices (07/01/2019-12/31/2023).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 2,207 patients, 32.7 % received PD-L1 testing before 1L therapy initiation, 17.4 % after 1L therapy initiation, and 50.0 % were never tested.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This study revealed low utilization of PD-L1 testing to guide treatment choice and impactful gaps between specimen collection, the receipt of results, and 1L therapy initiation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HPV testing rates in oropharyngeal squamous cell carcinoma
“Among the 146,176 patients with OPSCC and known HPV testing included in the study, the overall HPV testing rate was 88.4% (N = 129,240/146,176). Testing for HPV mediation significantly increased during the study period from 56.0% to 93.6% (adjusted odds ratio [OR]: 1.23, 95% CI: 1.22-1.24, P < .001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
HPV testing methods recommended by the College of American Pathologists
“For oropharyngeal tissue specimens (i.e. non-cytology), including regional lymph nodes with metastatic SCC and clinical findings consistent with an oropharyngeal primary, pathologists should perform HR-HPV testing by surrogate marker p16 IHC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pathologists should not routinely perform HR-HPV testing on patients with primary oral cavity, laryngeal, nasopharyngeal, or hypopharyngeal SCCs of the head and neck for prognostic purposes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Approaches to treatment
Current treatment options and standard of care
PD-1 inhibitor monotherapy
FDA-approved first-line indication: pembrolizumab as a single agent
KEYNOTE-048 design, stratification, and population
KEYNOTE-048 efficacy of pembrolizumab monotherapy at the interim analysis: CPS ≥1 and CPS ≥20 subgroups
| Endpoint | CPS ≥1 | CPS ≥20 |
|---|---|---|
| Participants, pembrolizumab 200 mg every 3 weeks | “n=257” | “n=133” |
| Participants, cetuximab with platinum and FU | “n=255” | “n=122” |
| Median OS, pembrolizumab, months (95% CI) | “12.3 (10.8, 14.9)” | “14.9 (11.6, 21.5)” |
| Median OS, cetuximab with platinum and FU, months (95% CI) | “10.3 (9.0, 11.5)” | “10.7 (8.8, 12.8)” |
| OS hazard ratio (95% CI) | “0.78 (0.64, 0.96)” | “0.61 (0.45, 0.83)” |
| Median PFS, pembrolizumab, months (95% CI) | “3.2 (2.2, 3.4)” | “3.4 (3.2, 3.8)” |
| Median PFS, cetuximab with platinum and FU, months (95% CI) | “5.0 (4.8, 5.8)” | “5.0 (4.8, 6.2)” |
| PFS hazard ratio (95% CI) | “1.15 (0.95, 1.38)” | “0.97 (0.74, 1.27)” |
| ORR, pembrolizumab (95% CI) | “19% (14.5, 24.4)” | “23% (16.4, 31.4)” |
| ORR, cetuximab with platinum and FU (95% CI) | “35% (29.1, 41.1)” | “36% (27.6, 45.3)” |
| Median duration of response, pembrolizumab, months (range) | “20.9 (1.5+, 34.8+)” | “20.9 (2.7, 34.8+)” |
| Median duration of response, cetuximab with platinum and FU, months (range) | “4.5 (1.2+, 28.6+)” | “4.2 (1.2+, 22.3+)” |
KEYNOTE-048 pembrolizumab monotherapy: final analysis and the CPS 1-19 subgroup
KEYNOTE-048 primary publication: pembrolizumab monotherapy overall survival
“Between April 20, 2015, and Jan 17, 2017, 882 participants were allocated to receive pembrolizumab alone (n=301), pembrolizumab with chemotherapy (n=281), or cetuximab with chemotherapy (n=300); of these, 754 (85%) had CPS of 1 or more and 381 (43%) had CPS of 20 or more.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At the second interim analysis, pembrolizumab alone improved overall survival versus cetuximab with chemotherapy in the CPS of 20 or more population (median 14·9 months vs 10·7 months, hazard ratio [HR] 0·61 [95% CI 0·45-0·83], p=0·0007) and CPS of 1 or more population (12·3 vs 10·3, 0·78 [0·64-0·96], p=0·0086) and was non-inferior in the total population (11·6 vs 10·7, 0·85 [0·71-1·03]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Neither pembrolizumab alone nor pembrolizumab with chemotherapy improved progression-free survival at the second interim analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“grade 3 or worse all-cause adverse events occurred in 164 (55%) of 300 treated participants in the pembrolizumab alone group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“pembrolizumab monotherapy is an appropriate first-line treatment for PD-L1-positive recurrent or metastatic HNSCC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
KEYNOTE-048 four-year follow-up: pembrolizumab monotherapy
“The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080), and 11.5 months (95% CI, 10.3 to 13.5) versus 10.7 months (95% CI, 9.3 to 12.1) in the total population (HR, 0.81; 95% CI, 0.68 to 0.97; nominal one-sided P = .00994; Figs 2A-2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pembrolizumab alone did not improve ORR compared with cetuximab-chemotherapy in the PD-L1 CPS ≥ 20, CPS ≥ 1, or total populations (Data Supplement).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A survival plateau at approximately 20% became apparent around the 4-year landmark for all patients receiving pembrolizumab alone.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KEYNOTE-048 five-year follow-up: pembrolizumab monotherapy
“Median OS remained longer for pembrolizumab versus EXTREME in the programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥ 20 (HR, 0.61; 95 % CI, 0.46-0.81) and CPS ≥ 1 populations (HR, 0.74; 95 % CI, 0.61-0.89), and similar in the total population (HR, 0.82; 95 % CI, 0.69-0.97).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The 5-year OS rate in the total population was 14.4 % for pembrolizumab versus 6.5 % for EXTREME” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pembrolizumab monotherapy by PD-L1 CPS subgroup: CPS 1-19 and CPS <1
“For pembrolizumab versus cetuximab-chemotherapy, the median overall survival was 7.9 versus 11.3 months in the PD-L1 CPS < 1 subgroup (hazard ratio [HR], 1.51 [95% CI, 0.96 to 2.37]) and 10.8 versus 10.1 months in the CPS 1-19 subgroup (HR, 0.86 [95% CI, 0.66 to 1.12]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the PD-L1 CPS < 1 subgroup, the ORR was 4.5% (n = 2; 95% CI, 0.6 to 15.5) for pembrolizumab versus 42.2% (n = 19; 95% CI, 27.7 to 57.8) for cetuximab-chemotherapy (Table 2 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the PD-L1 CPS 1-19 subgroup, the ORR was 14.5% (n = 18; 95% CI, 8.8 to 22.0) for pembrolizumab versus 33.8% (n = 45; 95% CI, 25.9 to 42.5) for cetuximab-chemotherapy (Table 2 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Efficacy outcomes for the PD-L1 CPS < 1 and CPS 1-19 subgroups (OS, PFS, and ORR) were not prespecified.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline recommendation: ASCO
PD-1 inhibitor plus platinum and fluorouracil
FDA-approved first-line indication: pembrolizumab with platinum and fluorouracil
KEYNOTE-048 regimen: pembrolizumab with platinum and fluorouracil
KEYNOTE-048 efficacy of pembrolizumab with platinum and fluorouracil at the interim analysis: overall population
| Endpoint | Pembrolizumab with platinum and FU | Cetuximab with platinum and FU |
|---|---|---|
| Participants | “n=281” | “n=278” |
| Median OS, months (95% CI) | “13.0 (10.9, 14.7)” | “10.7 (9.3, 11.7)” |
| OS hazard ratio (95% CI) | “0.77 (0.63, 0.93)” | Reference |
| Median PFS, months (95% CI) | “4.9 (4.7, 6.0)” | “5.1 (4.9, 6.0)” |
| PFS hazard ratio (95% CI) | “0.92 (0.77, 1.10)” | Reference |
| ORR (95% CI) | “36% (30.0, 41.5)” | “36% (30.7, 42.3)” |
| Median duration of response, months (range) | “6.7 (1.6+, 30.4+)” | “4.3 (1.2+, 27.9+)” |
KEYNOTE-048 pembrolizumab with platinum and fluorouracil: final analysis by CPS subgroup
KEYNOTE-048 primary publication: pembrolizumab with chemotherapy overall survival
“Pembrolizumab with chemotherapy improved overall survival versus cetuximab with chemotherapy in the total population (13·0 months vs 10·7 months, HR 0·77 [95% CI 0·63-0·93], p=0·0034) at the second interim analysis and in the CPS of 20 or more population (14·7 vs 11·0, 0·60 [0·45-0·82], p=0·0004) and CPS of 1 or more population (13·6 vs 10·4, 0·65 [0·53-0·80], p<0·0001) at final analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“235 (85%) of 276 in the pembrolizumab with chemotherapy group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the observed efficacy and safety, pembrolizumab plus platinum and 5-fluorouracil is an appropriate first-line treatment for recurrent or metastatic HNSCC” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
KEYNOTE-048 four-year follow-up: pembrolizumab with chemotherapy
“The median OS was 14.7 months (95% CI, 10.3 to 19.3) for pembrolizumab-chemotherapy versus 11.1 months (95% CI, 9.2 to 13.0) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.62; 95% CI, 0.46 to 0.84; nominal one-sided P = .00082), 13.6 months (95% CI, 10.7 to 15.5) versus 10.6 months (95% CI, 9.1 to 11.7) in the CPS ≥ 1 population (HR, 0.64; 95% CI, 0.53 to 0.78; nominal one-sided P = .00001), and 13.0 months (95% CI, 10.9 to 14.7) versus 10.7 months (95% CI, 9.3 to 11.7) in the total population (HR, 0.71; 95% CI, 0.59 to 0.85; nominal one-sided P = .00008; Figs 2D-2F).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 43.7% (13 CR/42 PR) for pembrolizumab-chemotherapy versus 38.2% (4 CR/38 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 37.2% (17 CR/73 PR) versus 35.7% (7 CR/77 PR) in the CPS ≥ 1 population, and 36.3% (18 CR/84 PR) versus 36.3% (8 CR/93 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Any-grade treatment-related AEs occurred in 58.3% (n = 175) of patients in the pembrolizumab-alone group, 95.7% (n = 264) in the pembrolizumab-chemotherapy group, and 96.9% (n = 278) in the cetuximab-chemotherapy group (Data Supplement).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade ≥ 3 treatment-related AEs were reported in 17.0% (n = 51), 71.7% (n = 198), and 69.3% (n = 199) of patients, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
KEYNOTE-048 five-year follow-up: pembrolizumab with chemotherapy
“Pembrolizumab-chemotherapy prolonged median OS in the PD-L1 CPS ≥ 20 (HR, 0.63; 95 % CI, 0.47-0.84), CPS ≥ 1 (HR, 0.65; 95 % CI, 0.53-0.79), and total (HR, 0.72; 95 % CI, 0.60-0.86) populations.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“16.0 % for pembrolizumab-chemotherapy versus 5.2 % for EXTREME” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“These 5-year follow-up results support the use of pembrolizumab and pembrolizumab-chemotherapy as first-line standards of care for R/M HNSCC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pembrolizumab with chemotherapy by PD-L1 CPS subgroup: CPS 1-19 and CPS <1
“For pembrolizumab-chemotherapy versus cetuximab-chemotherapy, the median overall survival was 11.3 versus 10.7 months in the PD-L1 CPS < 1 subgroup (HR, 1.21 [95% CI, 0.76 to 1.94]) and 12.7 versus 9.9 months in the CPS 1-19 subgroup (HR, 0.71 [95% CI, 0.54 to 0.94]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the PD-L1 CPS 1-19 subgroup, the ORR was 29.3% (n = 34; 95% CI, 21.2 to 38.5) for pembrolizumab-chemotherapy versus 33.6% (n = 42; 95% CI, 25.4 to 42.6) for cetuximab-chemotherapy (Table 2 ).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increased efficacy of pembrolizumab or pembrolizumab-chemotherapy was observed with increasing PD-L1 expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Guideline recommendation: ASCO
EGFR monoclonal antibody plus platinum-based chemotherapy
FDA-approved first-line indication: cetuximab with platinum-based therapy and fluorouracil
EXTREME design and regimen
EXTREME efficacy in the label
| Endpoint | Cetuximab with platinum-based therapy and fluorouracil | Platinum-based therapy and fluorouracil |
|---|---|---|
| Participants | “(n=222)” | “(n=220)” |
| Median OS, months | “10.1” | “7.4” |
| OS hazard ratio (95% CI) | “0.80 (0.64, 0.98)” | Reference |
| Median PFS, months | “5.5” | “3.3” |
| PFS hazard ratio (95% CI) | “0.57 (0.46, 0.72)” | Reference |
| ORR | “35.6%” | “19.5%” |
EXTREME primary publication
“Adding cetuximab to platinum-based chemotherapy with fluorouracil (platinum-fluorouracil) significantly prolonged the median overall survival from 7.4 months in the chemotherapy-alone group to 10.1 months in the group that received chemotherapy plus cetuximab (hazard ratio for death, 0.80; 95% confidence interval, 0.64 to 0.99; P=0.04).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The addition of cetuximab prolonged the median progression-free survival time from 3.3 to 5.6 months (hazard ratio for progression, 0.54; P<0.001) and increased the response rate from 20% to 36% (P<0.001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Sepsis occurred in 9 patients in the cetuximab group and in 1 patient in the chemotherapy-alone group (P=0.02).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Of 219 patients receiving cetuximab, 9% had grade 3 skin reactions and 3% had grade 3 or 4 infusion-related reactions.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
EXTREME safety in the label
Docetaxel, cisplatin, and cetuximab versus EXTREME: TPExtreme
“The TPEx regimen consisted of docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both intravenously on day 1, and cetuximab on days 1, 8, and 15 (intravenously 400 mg/m2 on day 1 of cycle 1 and 250 mg/m2 weekly subsequently).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall survival did not differ significantly between the groups (median 14·5 months [95% CI 12·5-15·7] in the TPEx group and 13·4 months [12·2-15·4] in the EXTREME group; hazard ratio 0·89 [95% CI 0·74-1·08]; p=0·23).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“214 (81%) of 263 patients in the TPEx group versus 246 (93%) of 265 patients in the EXTREME group had grade 3 or worse adverse events during chemotherapy (p<0·0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The TPEx regimen could provide an alternative to standard of care with the EXTREME regimen in the first-line treatment of patients with recurrent or metastatic HNSCC, especially for those who might not be good candidates for up-front pembrolizumab treatment.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cetuximab with chemotherapy as the KEYNOTE-048 comparator
“239 (83%) of 287 in the cetuximab with chemotherapy group” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse events led to death in 25 (8%) participants in the pembrolizumab alone group, 32 (12%) in the pembrolizumab with chemotherapy group, and 28 (10%) in the cetuximab with chemotherapy group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Guideline position of cetuximab with chemotherapy: ASCO
Guideline position of cetuximab with chemotherapy: NCCN
Cytotoxic chemotherapy
Chemotherapy responses without demonstrated survival benefit
Platinum plus fluorouracil versus methotrexate: randomized phase 3 trial
“Two hundred seventy-seven patients diagnosed with SCC of the head and neck were randomized to one of three treatments” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The complete and partial response rates were 32% for cisplatin plus 5-FU, 21% for carboplatin plus 5-FU, and 10% for MTX.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median response durations and median survival times were similar for all three treatment groups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“We conclude that combination chemotherapy resulted in improved response rates but was associated with an increased toxicity and no improvement in overall survival.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Cisplatin plus paclitaxel versus cisplatin plus fluorouracil: randomized phase 3 trial
“Two hundred eighteen patients with locally advanced, recurrent, or metastatic disease were randomly assigned to CF (cisplatin 100 mg/m2 day 1 and fluorouracil 1,000 mg/m2/24 hours by continuous intravenous infusion day 1 through 4) or CP (cisplatin 75 mg/m2 day 1 and paclitaxel 175 mg/m2 over 3 hours on day 1).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Estimated median survival was 8.7 months in the CF group and 8.1 month in the CP group. Objective response rate (complete response plus partial response) was 27% in the CF group and 26% in the CP group.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 12 deaths occurred (CF, seven; CP, five) during treatment” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Taxane in place of fluorouracil with pembrolizumab: single-arm phase 4 trial
“Patients received pembrolizumab 200 mg intravenously once every 3 weeks for ≤35 cycles and carboplatin AUC 5 mg/mL/min intravenously once every 3 weeks for ≤6 cycles and investigator's choice of paclitaxel 100 mg/m2 on days 1 and 8 or 175 mg/m2 on day 1, intravenously once every 3 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At this final analysis, 49 (49%) of 101 patients had an objective response (95% CI, 38.4 to 58.7), including seven patients (7%) with a confirmed complete response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of the 101 treated patients, grade 3-5 and serious treatment-related adverse events occurred in 76 (75%) and 27 (27%), respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pembrolizumab plus platinum plus taxane: United States real-world outcomes
“the toxicity of 5-FU has motivated the study of alternate combinations that replace 5-FU with a taxane.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The study population comprised 83 individuals (80.7% male) with a median age of 64 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median (95% CI) rwOS was 14.9 (8.8-23.3) months, rwToT was 5.3 (4.0-8.2) months” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Single-agent methotrexate, docetaxel, or cetuximab as the comparator after platinum
Single-agent standard therapy after platinum: response and survival in a phase 3 control arm
“The response rate was 13.3% in the nivolumab group versus 5.8% in the standard-therapy group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Treatment-related adverse events of grade 3 or 4 occurred in 13.1% of the patients in the nivolumab group versus 35.1% of those in the standard-therapy group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Therapies after progression on PD-1 inhibitor and platinum
Amivantamab and hyaluronidase-lpuj: indication and limitation of use
Amivantamab and hyaluronidase-lpuj: date of accelerated approval
OrigAMI-4: population and prior therapy
OrigAMI-4: efficacy results
| Outcome | RYBREVANT FASPRO (N=102) |
|---|---|
| Overall response rate (95% CI) | “42% (32%, 52%)” |
| Complete response | “15%” |
| Partial response | “28%” |
| Duration of response, range (months) | “1.4+, 19.7+” |
| Patients with duration of response of 6 months or longer | “56%” |
First approval in 10 years after prior platinum-based chemotherapy
Cetuximab monotherapy after platinum: indication and response
PD-1 inhibitors after platinum in disease not previously treated with a PD-1 inhibitor
Pembrolizumab versus methotrexate, docetaxel, or cetuximab after platinum: overall survival
Next-line therapy after first-line pembrolizumab in KEYNOTE-048
“The objective response rate on second-course pembrolizumab was 27.3% (3 of 11).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“PFS2 was similar after pembrolizumab and longer after pembrolizumab-chemotherapy on next-line taxanes and shorter after pembrolizumab and similar after pembrolizumab-chemotherapy on next-line nontaxanes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Salvage chemotherapy after anti-PD-(L)1 therapy: retrospective cohort
“Retrospective cohort analysis of 63 R/M patients treated with SCT after antiPD-(L1)-based therapy between January 2015 and August 2022.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Up to 71% received SCT as third line or beyond. ORR to SCT was 49% with higher rates in PD-L1 positive tumors, 71% vs. 18% (p=0.001), and cetuximab-containing regimens, 68% vs. 39% (p=0.026).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OS and PFS were 9.3 months (95% CI, 6.5–12.3) and 4.1 months (95% CI, 3.0–5.8) respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cetuximab-based salvage chemotherapy after immune checkpoint inhibitors: real-world cohort
“In recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) there is no established standard therapy after progression to immune checkpoint inhibitors (ICI).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among 80 patients, 96% and 100% received cetuximab-based first and second SCAI, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“First SCAI: ORR of 59% (41/70; 31 partial and 10 complete responses)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“DoR of 9.4 months, and PFS and OS of 5.9 and 12.4 months, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“grade 3–5 AEs, 38.7% (first SCAI) and 47% (second SCAI) with no toxic deaths.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Range of response and survival with conventional salvage regimens
“Conventional salvage regimens (taxanes, methotrexate, cetuximab) yield response rates of 21–69% but with short median PFS (2.9–5.5 months) and OS (6.3–13.3 months)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As a result, there is no clear standard of care choice in second-line treatment” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Salvage surgery and reirradiation for locoregional recurrence
Recurrent oral cavity cancer: surgery and radiation therapy by initial treatment
Recurrent laryngeal cancer: salvage surgery and reirradiation
Recurrent oropharyngeal cancer: surgical resection and additional radiation therapy
International consensus on reirradiation
“Reirradiation can be considered for some patients with recurrent or second primary head and neck squamous cell carcinoma arising within previously irradiated regions, a clinical scenario associated with few therapeutic options.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, evidence remains heterogeneous, and clinical choices are challenged by substantial variability in patient presentation, previous treatments, and toxicity risk.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Radiation therapy combined with immunotherapy for locoregional recurrence or oligometastatic disease
Salvage surgery versus nonsurgical management: meta-analysis
“Fifteen studies reported survival for salvage surgery and nonsurgical management of recurrence. Five-year OS ranged from 26% to 67% for the salvage surgery groups, compared to 0% to 32% for the nonsurgical management groups. Six studies reported HRs comparing salvage surgery to nonsurgical management; the pooled HR was 0.25 (95% CI [0.16, 0.38]; p < 0.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Salvage surgery and survival after progression of oropharyngeal cancer
Reirradiation with intensity-modulated radiotherapy: meta-analysis
“A total of 17 studies involving 1635 patients were included. Fourteen (82%) of those were retrospective, and 15 (88%) were from single institution. Reirradiation with IMRT produced pooled 2-year LC and OS rates of 52% (95% confidence interval [CI], 46%-57%) and 46% (95% CI, 41%-50%), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The pooled rates of late grade ≥ 3 and grade 5 toxicities were 26% (95% CI, 20%-32%) and 3.1% (95% CI, 2%-5%), respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Postoperative reirradiation with chemotherapy after salvage surgery: randomized trial
“Between 1999 and 2005, 130 patients with head and neck cancer were treated with salvage surgery and randomly assigned to full-dose reirradiation combined with chemotherapy (RT arm) or to observation” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At 2 years, 39% of patients in the RT arm and 10% in the WS arm experienced grade 3 or 4 late toxicity according to Radiation Therapy Oncology Group criteria (P = .06).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Full-dose reirradiation combined with chemotherapy after salvage surgery significantly improved DFS, but had no significant impact on OS.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Palliative reirradiation with chemotherapy versus methotrexate: randomized trial
“Due to a very slow accrual, the trial was closed after inclusion of 57 patients.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“re-irradiation did not improve OS compared with methotrexate (23% versus 22% at 1year, NS).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of current therapies
Summary: response, survival, and PD-L1 selection with first-line pembrolizumab regimens
Pembrolizumab monotherapy is approved for first-line recurrent or metastatic HNSCC with PD-L1 CPS ≥1, and pembrolizumab with platinum and fluorouracil for all first-line patients. ASCO states that “Response rates to single-agent pembrolizumab remain close to 20%, regardless of prior exposure to therapy or PD-L1 expression”. At the KEYNOTE-048 4-year follow-up, the objective response rate with pembrolizumab alone was 19.1% versus 34.9% with cetuximab-chemotherapy in the CPS ≥1 population and 16.9% versus 36.0% in the total population; with pembrolizumab-chemotherapy it was 37.2% (CPS ≥1) and 36.3% (total). Neither pembrolizumab regimen improved progression-free survival at the second interim analysis, when median progression-free survival in the CPS ≥1 subgroup was 3.2 months with pembrolizumab versus 5.0 months with cetuximab-chemotherapy. At the 4-year follow-up, median overall survival was 12.3 months with pembrolizumab (CPS ≥1) and 13.0 months with pembrolizumab-chemotherapy (total population); 5-year overall survival in the total population was 14.4% and 16.0%, and the survival curve with pembrolizumab alone reached a plateau at approximately 20%. The median duration of pembrolizumab exposure was 3.5 months with monotherapy and 5.8 months in the combination arm. In exploratory analyses that were not prespecified, median overall survival with pembrolizumab alone versus cetuximab-chemotherapy was 10.8 versus 10.1 months in the CPS 1-19 subgroup (hazard ratio 0.86, 95% CI 0.66 to 1.12), and median overall survival was 7.9 versus 11.3 months in the CPS <1 subgroup (hazard ratio 1.51, 95% CI 0.96 to 2.37).
Summary: toxicity and administration of chemotherapy-containing regimens
At the KEYNOTE-048 4-year follow-up, grade ≥3 treatment-related adverse events occurred in 17.0% of participants receiving pembrolizumab alone, 71.7% receiving pembrolizumab-chemotherapy, and 69.3% receiving cetuximab-chemotherapy. Fluorouracil requires a “continuous 4-day infusion” and is associated with “cardiovascular and gastrointestinal toxicities”. In EXTREME, fatal cardiac disorders or sudden death occurred in 3% of 219 participants treated with cetuximab plus platinum and fluorouracil. With a taxane in place of fluorouracil alongside pembrolizumab and carboplatin, grade 3 to 5 treatment-related adverse events occurred in 76 of 101 treated participants (75%). NCI states that chemotherapy has been shown to induce responses with no demonstrated increase in survival; in randomized trials, cisplatin plus fluorouracil did not improve overall survival over methotrexate, and response rates were 32% with cisplatin plus fluorouracil and 10% with methotrexate in one trial, and 27% with cisplatin plus fluorouracil and 26% with cisplatin plus paclitaxel in another.
Summary: outcomes in HPV-negative disease
Response and survival with current therapy are lower in HPV-negative than in HPV-positive disease. In Argiris et al. (2014), the objective response rate was 19% for HPV-negative versus 55% for HPV-positive tumors, and median survival was 6.7 versus 12.9 months. After progression of oropharyngeal cancer, 2-year overall survival was 27.6% for p16-negative versus 54.6% for p16-positive disease. With first-line pembrolizumab in U.S. practice, median real-world overall survival in HPV-negative versus HPV-positive disease was 9 versus 20 months on monotherapy and 7 versus 15 months with chemotherapy. ASCO states that current data “do not support changing recommendations” for anti-PD-1 therapy “with regard to the HPV status.”
Summary: options after progression and for locoregional recurrence
The FDA states that approved therapies after platinum-based chemotherapy are associated with an overall response rate of around 20% or less. On November 5, 2026, amivantamab and hyaluronidase-lpuj received accelerated approval after progression on platinum-based chemotherapy and an anti-PD-(L)1 antibody, excluding HPV-associated oropharyngeal squamous cell carcinoma, based on an overall response rate of 42% in the 102-participant primary efficacy population of OrigAMI-4, a multicenter, open-label, multi-cohort trial. Conventional salvage regimens yield response rates of 21% to 69%, median progression-free survival of 2.9 to 5.5 months, and median overall survival of 6.3 to 13.3 months, and a review states that there is “no clear standard of care choice in second-line treatment”. For locoregional recurrence after prior radiation, reirradiation with intensity-modulated radiotherapy had pooled late grade ≥3 and grade 5 toxicity rates of 26% and 3.1%, and postoperative reirradiation with chemotherapy after salvage surgery improved disease-free survival without a significant effect on overall survival.
Response rates with pembrolizumab monotherapy
Objective response in KEYNOTE-048 at 4-year follow-up
“Pembrolizumab alone did not improve ORR compared with cetuximab-chemotherapy in the PD-L1 CPS ≥ 20, CPS ≥ 1, or total populations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 43.7% (13 CR/42 PR) for pembrolizumab-chemotherapy versus 38.2% (4 CR/38 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 37.2% (17 CR/73 PR) versus 35.7% (7 CR/77 PR) in the CPS ≥ 1 population, and 36.3% (18 CR/84 PR) versus 36.3% (8 CR/93 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term survival plateau in KEYNOTE-048
“A survival plateau at approximately 20% became apparent around the 4-year landmark for all patients receiving pembrolizumab alone. For patients receiving pembrolizumab-chemotherapy, a survival plateau at approximately 30% was observed for the PD-L1 CPS ≥ 20 population and at approximately 20% for the CPS ≥ 1 and total populations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-related adverse events with pembrolizumab plus chemotherapy
“Any-grade treatment-related AEs occurred in 58.3% (n = 175) of patients in the pembrolizumab-alone group, 95.7% (n = 264) in the pembrolizumab-chemotherapy group, and 96.9% (n = 278) in the cetuximab-chemotherapy group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade ≥ 3 treatment-related AEs were reported in 17.0% (n = 51), 71.7% (n = 198), and 69.3% (n = 199) of patients, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fluorouracil administration and toxicity
“However, FU is associated with potential challenges (continuous 4-day infusion, high administration costs, and cardiovascular and gastrointestinal toxicities), creating a clinical need for alternative chemotherapy combinations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiac deaths with cetuximab plus platinum and fluorouracil
HPV-negative disease: response and survival with first-line chemotherapy
“The objective response rate was 55% for HPV-positive versus 19% for HPV-negative (P = 0.022), and 50% for p16-positive versus 19% for p16-negative (P = 0.057).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median survival was 12.9 versus 6.7 months for HPV-positive versus HPV-negative patients (P = 0.014), and 11.9 versus 6.7 months for p16-positive versus p16-negative patients (P = 0.027).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HPV-negative disease: survival after progression of oropharyngeal cancer
HPV-negative disease: real-world survival with first-line pembrolizumab
“Among those receiving pembrolizumab monotherapy, the median rwOS was 20 months for those with HPV-positive tumors versus 9 months for those with HPV-negative tumors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among individuals receiving pembrolizumab plus chemotherapy, the median rwOS was 15 months for those with HPV-positive tumors versus 7 months for those with HPV-negative tumors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prognosis and later-line options before immunotherapy
“The prognosis of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains poor, with a guarded median overall survival (OS) ranging from 10 months to 14 months” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Upon progression, the only treatment option was single-agent chemotherapy, with limited response rates and a median survival of 6 months” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Unmet need stated by the FDA
Unmet need after immune checkpoint inhibitor failure
“The challenge of R/M HNSCC after immune checkpoint inhibitor (ICI) failure represents one of the most pressing unmet needs in oncology.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Between 60 and 80% of patients develop resistance, and historical salvage regimens like cytotoxic chemotherapy or chemotherapy plus cetuximab rarely extend median overall survival (mOS) beyond one year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Place in treatment, anticipated use, and care setting
Summary: target population
The Breakthrough Therapy Designation covers ficerafusp alfa with pembrolizumab “for the first line (1L) treatment of patients with metastatic or with unresectable, recurrent (R/M) head and neck squamous cell carcinoma (HNSCC) whose tumors express programmed death-ligand 1 with combined positive score (CPS) ≥1, excluding human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma.” The pivotal FORTIFI-HN01 trial (NCT06788990) enrolls recurrent or metastatic HNSCC with a primary tumor in the “oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC)”; paranasal sinus and nasopharyngeal primaries are excluded. The EU trial record requires “documentation of HPV-negative disease per central testing performed if presenting with OPSCC”, and lists the development of an HPV DNA assay among the sponsor's delegated duties. HPV status is therefore established by testing only for oropharyngeal primaries; Bicara states that HPV testing is “typically only being conducted in tumors originating from the oropharynx”, and the College of American Pathologists recommends against routine HR-HPV testing of primary oral cavity, laryngeal, nasopharyngeal, and hypopharyngeal carcinomas for prognostic purposes. Participants must have “PD-L1 CPS ≥1”, which the EU record specifies as “PD-L1 immunohistochemistry [IHC] via 22C3” in participants eligible “to receive pembrolizumab as frontline monotherapy”. Other criteria are no prior systemic therapy in the recurrent or metastatic setting, systemic therapy for locoregionally advanced disease completed more than 6 months earlier, no prior anti-EGFR antibody outside radiosensitizing or multimodal treatment, no immune checkpoint inhibitor within 6 months, measurable disease by RECIST 1.1, ECOG performance status 0 or 1, and no higher risk of bleeding.
Summary: position relative to current first-line therapy
Ficerafusp alfa would be added to pembrolizumab in first-line treatment, the setting in which pembrolizumab monotherapy (CPS ≥1) and pembrolizumab with platinum and fluorouracil are FDA approved, offered by ASCO with a strong recommendation for CPS ≥1, and listed by NCCN as preferred first-line options. The intended population overlaps the pembrolizumab monotherapy label population, which requires CPS ≥1 by an FDA-authorized test. Hanna et al. state that the combination “could provide a chemotherapy-free regimen”. Bicara reports a “two-to-three-fold increase in median OS” relative to pembrolizumab monotherapy or pembrolizumab with chemotherapy, and states that “No head-to-head studies have been conducted, and cross-trial comparisons may not be reliable”. The available results for ficerafusp alfa are from a single-arm phase 1b trial; topline results of the FORTIFI-HN01 interim analysis are expected in mid-2027, with a potential U.S. launch in 2028.
Summary: anticipated use and care setting
Bicara estimates about 50,000 HPV-negative patients newly diagnosed each year in the United States, EU5, and Japan, about 18,000 of them in the United States, and states that 80% of recurrent or metastatic HNSCC is HPV-negative. In KEYNOTE-048, 85% of tumors had CPS ≥1; among U.S. real-world first-line pembrolizumab recipients with a CPS result (352 participants, 54.5% of the cohort), 83.8% had CPS ≥1. In a U.S. nationwide database drawn primarily from community practices, 32.7% of 2,207 participants with recurrent or metastatic HNSCC received PD-L1 testing before first-line therapy and 50.0% were never tested. In the phase 1b trial, ficerafusp alfa 1,500 mg was given intravenously on days 1, 8, and 15 of 21-day cycles with pembrolizumab 200 mg on day 1; the protocol specifies a 120-minute infusion, extendable to 4 hours, and observation with vital-sign monitoring for 2 hours after the first 2 doses. Bicara is developing a less frequent dosing regimen. Among U.S. real-world first-line pembrolizumab recipients, 583 (90.2%) were treated in community practices and 57 (8.8%) in academic practices.
Target population named in the Breakthrough Therapy Designation
Intended first-line use in combination with pembrolizumab
Share of recurrent or metastatic disease that is HPV-negative
Positioning relative to pembrolizumab-based standard of care
Proposed chemotherapy-free first-line regimen
Weekly intravenous administration with pembrolizumab every 3 weeks
Infusion duration and post-infusion observation in the phase 1b protocol
Less frequent dosing under evaluation for patients and providers
Practice setting of first-line pembrolizumab in U.S. real-world data
| Practice type of individuals receiving first-line pembrolizumab | All, n (%) | Monotherapy, n (%) | With chemotherapy, n (%) |
|---|---|---|---|
| Community | “583 (90.2)”View highlighted excerpt for this quote | “384 (89.1)”View highlighted excerpt for this quote | “199 (92.6)”View highlighted excerpt for this quote |
| Academic | “57 (8.8)”View highlighted excerpt for this quote | “43 (10.0)”View highlighted excerpt for this quote | “14 (6.5)”View highlighted excerpt for this quote |
Heterogeneity of treatment effect
HPV status: response at 1500 mg weekly in the phase 1b cohort
HPV status: progression-free and overall survival at 1500 mg weekly
HPV status at an earlier data cut of the same cohort
PD-L1 CPS 1-19 versus 20 or greater at 1500 mg weekly
Locoregional recurrence, tumor burden, and performance status at 1500 mg weekly
Confirmed response by CPS, tumor burden, and disease extent across the three dose cohorts
| Subgroup, % (n/N) | 750 mg weekly (n=30) | 1500 mg weekly (n=28) | 2000 mg every 2 weeks (n=27) |
|---|---|---|---|
| CPS 1-19 | “73 (8/11)” | “54 (7/13)” | “57 (8/14)” |
| CPS 20 or greater | “47 (9/19)” | “53 (8/15)” | “38 (5/13)” |
| Sum of target lesion diameters 50 mm or less | “55 (11/20)” | “53 (8/15)” | “53 (9/17)” |
| Sum of target lesion diameters greater than 50 mm | “60 (6/10)” | “54 (7/13)” | “40 (4/10)” |
| Sum of target lesion diameters greater than 70 mm | “50 (2/4)” | “43 (3/7)” | “33 (2/6)” |
| Locoregional disease only | “38 (6/16)” | “62 (5/8)” | “50 (7/14)” |
| Distant metastatic disease only | “100 (5/5)” | “29 (2/7)” | “40 (2/5)” |
| Locoregional and distant metastatic disease | “67 (6/9)” | “62 (8/13)” | “50 (4/8)” |
Dose cohort: response depth and progression-free survival
| Dose cohort | Confirmed ORR (95% CI) | Complete response | Responders with deep response | Median PFS (95% CI), months |
|---|---|---|---|---|
| 750 mg weekly | “57% (37%-74%)” | “13%” | “47% (8/17)” | “6.9 (4.6-NE)” |
| 1500 mg weekly | “54% (34%-72%)” | “25%” | “80% (12/15)” | “9.9 (4.4-22.7)” |
| 2000 mg every 2 weeks | “48% (29%-68%)” | “30%” | “77% (10/13)” | “12.7 (4.9-NE)” |
Dose cohort: 1500 mg versus 750 mg weekly at the December 2025 data cut
Pembrolizumab monotherapy in KEYNOTE-048 by PD-L1 CPS
“The median OS was 14.9 months (95% CI, 11.5 to 20.6) for pembrolizumab alone versus 10.8 months (95% CI, 8.8 to 12.8) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population (HR, 0.61; 95% CI, 0.46 to 0.81; nominal one-sided P = .00034), 12.3 months (95% CI, 10.8 to 14.8) versus 10.4 months (95% CI, 9.0 to 11.7) in the CPS ≥ 1 population (HR, 0.74; 95% CI, 0.61 to 0.89; nominal one-sided P = .00080), and 11.5 months (95% CI, 10.3 to 13.5) versus 10.7 months (95% CI, 9.3 to 12.1) in the total population (HR, 0.81; 95% CI, 0.68 to 0.97; nominal one-sided P = .00994” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pembrolizumab in KEYNOTE-048: CPS 1-19 and CPS less than 1 subgroups
“For pembrolizumab versus cetuximab-chemotherapy, the median overall survival was 7.9 versus 11.3 months in the PD-L1 CPS < 1 subgroup (hazard ratio [HR], 1.51 [95% CI, 0.96 to 2.37]) and 10.8 versus 10.1 months in the CPS 1-19 subgroup (HR, 0.86 [95% CI, 0.66 to 1.12]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Increased efficacy of pembrolizumab or pembrolizumab-chemotherapy was observed with increasing PD-L1 expression.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Pembrolizumab in KEYNOTE-048: other subgroups and HPV status
“In subgroup analyses, HRs generally favored pembrolizumab alone except for recurrent-only disease (locally recurrent disease and disease that spread to cervical lymph nodes” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“including in patients with poor prognostic markers such as smoking history and HPV-negative oropharyngeal cancer.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Real-world first-line pembrolizumab by HPV status and primary site
“Among those receiving pembrolizumab monotherapy, the median rwOS was 20 months for those with HPV-positive tumors versus 9 months for those with HPV-negative tumors; 17 months for those with an ECOG PS of 0–1 versus 6 months for those with an ECOG PS of 2–4; and 13 months for those with oropharyngeal tumors versus 9 months for those with tumors of the larynx, 5 months for those with oral cavity tumors, and 6 months for individuals with tumors of the hypopharynx” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among individuals receiving pembrolizumab plus chemotherapy, the median rwOS was 15 months for those with HPV-positive tumors versus 7 months for those with HPV-negative tumors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Care management intervention strategies
Prophylaxis and treatment of acneiform dermatitis in the phase 1b cohort
Protocol prophylactic skin measures and suggested treatment of rash
Premedication and management of infusion-related reactions
HPV testing by primary site
“For oropharyngeal tissue specimens (i.e. non-cytology), including regional lymph nodes with metastatic SCC and clinical findings consistent with an oropharyngeal primary, pathologists should perform HR-HPV testing by surrogate marker p16 IHC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Unlike the oropharynx, identifying HPV in primary oral cavity, laryngeal, and hypopharyngeal SCCs does not have clear and consistent implications for patient prognosis or patient management” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For oropharyngeal cancer, p16 IHC is strongly recommended” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For recurrent and/or metastatic SCCHN, tumour PD-L1 expression should be evaluated” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
PD-L1 testing for pembrolizumab monotherapy
HPV and PD-L1 testing in the pivotal trial
HPV testing method in the phase 1b protocol
Other product development or post-marketing obligations required by the FDA
Not applicable.
Ongoing post-approval monitoring
Not applicable.